Corbus Pharmaceuticals Holdings (Nasdaq: CRBP) reported disappointing results from a Phase 2 study of anabasum to treat cystic fibrosis sending this stock price down $1.05 to close at $7.95.
Corbus Pharmaceuticals reports disappointing results
March 30, 2017 at 17:50 PM EDT
